There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for FBLG is 26.84M and currently, short sellers hold a 8.37% ratio of that float. The average trading volume of FBLG on October 22, 2024 was 423.26K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FBLG) stock’s latest price update
The stock price of FibroBiologics Inc (NASDAQ: FBLG) has plunged by -9.88 when compared to previous closing price of 3.39, but the company has seen a 13.15% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-18 that HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development, testing, and manufacturing solutions provider established a master services agreement to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for utilization in a diabetic foot ulcer (DFU) clinical trial slated to begin in 2025.
FBLG’s Market Performance
FBLG’s stock has risen by 13.15% in the past week, with a monthly drop of -7.42% and a quarterly drop of -37.53%. The volatility ratio for the week is 17.10% while the volatility levels for the last 30 days are 13.85% for FibroBiologics Inc The simple moving average for the past 20 days is 6.01% for FBLG’s stock, with a -58.55% simple moving average for the past 200 days.
Analysts’ Opinion of FBLG
Many brokerage firms have already submitted their reports for FBLG stocks, with Maxim Group repeating the rating for FBLG by listing it as a “Buy.” The predicted price for FBLG in the upcoming period, according to Maxim Group is $12 based on the research report published on September 24, 2024 of the current year 2024.
FBLG Trading at 24.04% from the 50-Day Moving Average
After a stumble in the market that brought FBLG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.45% of loss for the given period.
Volatility was left at 13.85%, however, over the last 30 days, the volatility rate increased by 17.10%, as shares surge +10.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +55.08% upper at present.
During the last 5 trading sessions, FBLG rose by +13.15%, in comparison to the 20-day moving average, which settled at $2.88. In addition, FibroBiologics Inc saw -89.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FBLG starting from O’HEERON PETE, who purchase 8,500 shares at the price of $1.91 back on Aug 12 ’24. After this action, O’HEERON PETE now owns 6,056,647 shares of FibroBiologics Inc, valued at $16,269 using the latest closing price.
Khoja Hamid, the Chief Scientific Officer of FibroBiologics Inc, purchase 10,000 shares at $1.90 during a trade that took place back on Aug 12 ’24, which means that Khoja Hamid is holding 11,250 shares at $19,000 based on the most recent closing price.
Stock Fundamentals for FBLG
The total capital return value is set at 9.18.
Based on FibroBiologics Inc (FBLG), the company’s capital structure generated -3.33 points at debt to capital in total, while cash flow to debt ratio is standing at -4.88. The debt to equity ratio resting at -0.77. The interest coverage ratio of the stock is -1120.5.
Currently, EBITDA for the company is -8.45 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.
Conclusion
In conclusion, FibroBiologics Inc (FBLG) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
